Compare Davita Inc (DVA) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Meta Platforms Inc — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Meta Platforms Inc trades at $662.67 (market cap $1.68T). The key difference: Meta Platforms Inc is far larger — about 112.6× Davita Inc's market cap, and Meta Platforms Inc pays a 0.32% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | META | |
|---|---|---|
Market Cap | $14.92B | $1.68T |
Sector | Health | Media |
52-Week High | $235.71 | $790.00 |
52-Week Low | $103.87 | $525.72 |
Enterprise Value | $27.47B | $1.68T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Meta Platforms (META) trades at $656.73, down 1.86% on the day, but maintains strong technical momentum with a bullish moving average signal and key resistance at $663. Fundamentally, the company demonstrates robust profitability with 32.84% net income margin and consistent earnings beats, including Q1 2026 EPS of $10.44 versus $6.70 expected. Recent AI developments, including the Muse Spark launch on April 10, 2026, highlight growth initiatives.
The outlook remains positive with 79% analyst buy ratings and a $815.44 consensus price target suggesting 24% upside. Key risks include ongoing litigation, particularly the Massachusetts youth addiction lawsuit ruled on April 10, 2026, and elevated capital expenditures. Revenue growth trajectory and AI monetization present significant opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
